ARCHIVES

Modality Combo Decreases Prostate Cancer Recurrence

This article is from The Cancer Letter archive.

Vol. 27 No. 8 | August 27, 2004

Download PDF Visit The Full Archive

Related Articles

Sorafenib Targets AML Driven By Mutant FLT3 Gene

February 29, 2008

NCI Agrees To give NSABP One Year Until Competition; Advisors OK Concept

June 17, 1994

FDA Expands Nexavar Indication To Include Thyroid Cancer

December 27, 2013

Treatment research Reports Summarized; New MTX Rescues

May 6, 1977

Movement To Resolve Patient Care Reimbursement Problems Gains Momentum; NCI Report Adds Fuel

March 17, 1989

In Brief: MD Anderson’s DuBois Named head of Arizona State’s Biodesign Institute

October 5, 2012